BTIG Research Trims Mersana Therapeutics (NASDAQ:MRSN) Target Price to $10.00

Mersana Therapeutics (NASDAQ:MRSN – Get Rating) had its price objective cut by BTIG Research from $16.00 to $10.00 in a report issued on Thursday, The Fly reports. Several other brokerages have also recently weighed in on MRSN. JPMorgan Chase & Co. raised Mersana Therapeutics from a neutral rating to an overweight rating and set a […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Mikhail Papisov ,Upifitamab Rilsodotin Upri ,Advisors Inc ,Sphera Funds Management ,Mersana Therapeutics Inc ,Life Insurance Co ,Jpmorgan Chase Co ,Virtu Financial ,Mersana Therapeutics Company Profile ,Mersana Therapeutics ,Get Rating ,Moderate Buy ,Therapeutics Stock Down ,Funds Management ,Upifitamab Rilsodotin ,Mersana Therapeutics Daily ,